Skip to main content

NYSE:USPH - U.S. Physical Therapy Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $132.50
  • Forecasted Upside: 12.95 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$117.31
▲ +0.77 (0.66%)
1 month | 3 months | 12 months
Get New U.S. Physical Therapy Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for USPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for USPH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$132.50
▲ +12.95% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for U.S. Physical Therapy in the last 3 months. The average price target is $132.50, with a high forecast of $135.00 and a low forecast of $130.00. The average price target represents a 12.95% upside from the last price of $117.31.

Buy

The current consensus among 2 investment analysts is to buy stock in U.S. Physical Therapy. This rating has held steady since March 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/18/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00N/A
i
Rating by M. Petusky at Barrington Research
5/10/2021Jefferies Financial GroupUpgradeHold ➝ Buy$130.00 ➝ $135.00N/A
i
5/7/2021Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00Medium
i
Rating by M. Petusky at Barrington Research
5/3/2021Jefferies Financial GroupUpgradeHold ➝ Buy$130.00 ➝ $135.00High
i
3/4/2021Barrington ResearchReiterated RatingOutperform ➝ Market PerformN/A
i
Rating by M. Petusky at Barrington Research
2/26/2021Barrington ResearchDowngradeOutperform ➝ Market PerformLow
i
Rating by M. Petusky at Barrington Research
8/7/2020Barrington ResearchBoost Price TargetOutperform$95.00 ➝ $100.00Low
i
6/8/2020Barrington ResearchBoost Price TargetOutperform$84.00 ➝ $95.00Low
i
4/30/2020SidotiDowngradeBuy ➝ NeutralHigh
i
Rating by Mitra Ramgopal at Sidoti
3/27/2020SidotiLower Price TargetBuy$128.00 ➝ $80.00Medium
i
Rating by Mitra Ramgopal at Sidoti
3/17/2020William BlairDowngradeOutperform ➝ HoldHigh
i
Rating by Matt Larew at William Blair
3/11/2020SidotiUpgradeNeutral ➝ Buy$128.00Medium
i
2/28/2020Barrington ResearchLower Price TargetOutperform$130.00 ➝ $120.00High
i
Rating by M. Petusky at Barrington Research
1/31/2020William BlairReiterated RatingBuyMedium
i
Rating by Matt Larew at William Blair
11/8/2019Barrington ResearchUpgradeMarket Perform ➝ Outperform$130.00High
i
Rating by M. Petusky at Barrington Research
5/3/2019Barrington ResearchReiterated RatingHoldLow
i
3/7/2019William BlairInitiated CoverageOutperform ➝ Outperform$106.61Medium
i
Rating by M. Larew at William Blair
11/2/2018Cantor FitzgeraldBoost Price TargetNeutral ➝ Neutral$103.00 ➝ $107.00Low
i
Rating by J. France at Cantor Fitzgerald
8/3/2018Jefferies Financial GroupReiterated RatingHold$105.00Low
i
Rating by Brian Tanquilut at Jefferies Financial Group Inc.
8/3/2018Barrington ResearchReiterated RatingHoldMedium
i
5/4/2018Cantor FitzgeraldDowngradeOverweight ➝ NeutralLow
i
Rating by J. France at Cantor Fitzgerald
5/3/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Buy$90.00Low
i
4/25/2018SidotiDowngradeBuy ➝ NeutralHigh
i
3/9/2018Cantor FitzgeraldBoost Price TargetOverweight$90.00Low
i
3/9/2018Barrington ResearchReiterated RatingHoldHigh
i
Rating by M. Petusky at Barrington Research
2/23/2018Jefferies Financial GroupSet Price TargetHold$76.00Low
i
1/9/2018Cantor FitzgeraldReiterated RatingBuy$80.00Low
i
Rating by J. France at Cantor Fitzgerald
11/3/2017Barrington ResearchDowngradeOutperform ➝ Market PerformN/A
i
Rating by M. Petusky at Barrington Research
11/2/2017Cantor FitzgeraldReiterated RatingBuy$74.00N/A
i
Rating by J. France at Cantor Fitzgerald
9/26/2017Cantor FitzgeraldReiterated RatingBuy$72.00Low
i
Rating by J. France at Cantor Fitzgerald
9/8/2017SidotiUpgradeNeutral ➝ Buy$62.00 ➝ $74.00Low
i
8/4/2017Jefferies Financial GroupSet Price TargetHold$65.00Low
i
7/24/2017Cantor FitzgeraldInitiated CoverageOverweight$72.00High
i
Rating by J. France at Cantor Fitzgerald
7/3/2017Barrington ResearchUpgradeMarket Perform ➝ Outperform$68.00High
i
Rating by M. Petusky at Barrington Research
6/30/2017Jefferies Financial GroupReiterated RatingHold$63.00Low
i
3/18/2017Jefferies Financial GroupSet Price TargetHold$63.00Low
i
3/17/2017Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
i
Rating by M. Petusky at Barrington Research
12/5/2016Jefferies Financial GroupReiterated RatingHold$60.00 ➝ $63.00N/A
i
11/7/2016JMP SecuritiesReiterated RatingHoldN/A
i
11/7/2016Jefferies Financial GroupLower Price TargetHold$60.00N/A
i
11/4/2016Barrington ResearchUpgradeMarket Perform ➝ Outperform$61.00N/A
i
Rating by M. Petusky at Barrington Research
8/5/2016Jefferies Financial GroupSet Price TargetHold$53.00 ➝ $65.00N/A
i
8/5/2016Barrington ResearchDowngradeOutperform ➝ Market PerformN/A
i
Rating by M. Petusky at Barrington Research
(Data available from 5/18/2016 forward)
U.S. Physical Therapy logo
U.S. Physical Therapy, Inc., through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The company provides industrial injury prevention services, including onsite injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments through physical therapists and specialized certified athletic trainers for Fortune 500 companies, and other clients comprising insurers and their contractors. As of December 31, 2020, it operated 544 outpatient physical therapy clinics in 39 states; and managed 38 physical therapy facilities. The company was founded in 1990 and is based in Houston, Texas.
Read More

Today's Range

Now: $117.31
$117.21
$118.49

50 Day Range

MA: $111.87
$103.85
$119.16

52 Week Range

Now: $117.31
$67.55
$143.67

Volume

43 shs

Average Volume

73,226 shs

Market Capitalization

$1.51 billion

P/E Ratio

49.92

Dividend Yield

1.20%

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of U.S. Physical Therapy?

The following Wall Street research analysts have issued research reports on U.S. Physical Therapy in the last twelve months: Barrington Research, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for USPH.

What is the current price target for U.S. Physical Therapy?

2 Wall Street analysts have set twelve-month price targets for U.S. Physical Therapy in the last year. Their average twelve-month price target is $132.50, suggesting a possible upside of 13.7%. Jefferies Financial Group Inc. has the highest price target set, predicting USPH will reach $135.00 in the next twelve months. Barrington Research has the lowest price target set, forecasting a price of $130.00 for U.S. Physical Therapy in the next year.
View the latest price targets for USPH.

What is the current consensus analyst rating for U.S. Physical Therapy?

U.S. Physical Therapy currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe USPH will outperform the market and that investors should add to their positions of U.S. Physical Therapy.
View the latest ratings for USPH.

What other companies compete with U.S. Physical Therapy?

How do I contact U.S. Physical Therapy's investor relations team?

U.S. Physical Therapy's physical mailing address is 1300 WEST SAM HOUSTON PARKWAY SUITE 300, HOUSTON TX, 77042. The company's listed phone number is 713-297-7000 and its investor relations email address is [email protected] The official website for U.S. Physical Therapy is www.usph.com.